Coach (COH) Reaches $42.95 52-Week High, Cellectis SA (ADR) (CLLS) Had 3 Bulls

The stock of Coach Inc (NYSE:COH) hit a new 52-week high and has $44.67 target or 4.00% above today’s $42.95 share price. The 9 months bullish chart indicates low risk for the $13.42 billion company. The 1-year high was reported on May, 3 by Barchart.com. If the $44.67 price target is reached, the company will be worth $536.80M more. About 1.27M shares traded. Coach Inc (NYSE:COH) has risen 21.31% since September 26, 2016 and is uptrending. It has outperformed by 9.89% the S&P500.

Among 3 analysts covering Cellectis (NASDAQ:CLLS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cellectis had 3 analyst reports since April 5, 2016 according to SRatingsIntel. Wells Fargo initiated the shares of CLLS in report on Tuesday, February 28 with “Outperform” rating. As per Tuesday, April 5, the company rating was initiated by Ladenburg Thalmann. See Cellectis SA (ADR) (NASDAQ:CLLS) latest ratings:

02/03/2017 Broker: Nomura Rating: Buy Initiates Coverage On
28/02/2017 Broker: Wells Fargo Rating: Outperform Initiate

Investors sentiment decreased to 0.91 in Q4 2016. Its down 0.21, from 1.12 in 2016Q3. It fall, as 51 investors sold Coach Inc shares while 196 reduced holdings. 59 funds opened positions while 167 raised stakes. 233.71 million shares or 3.77% less from 242.86 million shares in 2016Q3 were reported. Suntrust Banks has 95,362 shares for 0.02% of their portfolio. Bell Bankshares has invested 0.8% in Coach Inc (NYSE:COH). Amer Research & Co holds 2,920 shares. 594,227 are owned by Millennium Mgmt Lc. Apriem Advsr has invested 0% of its portfolio in Coach Inc (NYSE:COH). Intrepid Cap Mgmt holds 161,570 shares. Rodgers Brothers reported 42,075 shares. Commonwealth Equity Services holds 40,089 shares. Amica Retiree Med holds 0.06% or 2,219 shares. 33,700 are owned by Nikko Asset Mgmt Americas. Smithfield Trust has invested 0.01% of its portfolio in Coach Inc (NYSE:COH). Dimensional Fund Lp reported 1.11 million shares. Cibc World Mkts stated it has 0.01% of its portfolio in Coach Inc (NYSE:COH). Cwm holds 63,061 shares or 0.14% of its portfolio. Burt Wealth owns 0% invested in Coach Inc (NYSE:COH) for 90 shares.

Among 33 analysts covering Coach Inc. (NYSE:COH), 19 have Buy rating, 1 Sell and 13 Hold. Therefore 58% are positive. Coach Inc. has $51 highest and $27 lowest target. $38.36’s average target is -10.69% below currents $42.95 stock price. Coach Inc. had 54 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, January 27. The stock of Coach Inc (NYSE:COH) earned “Buy” rating by Oppenheimer on Friday, April 7. As per Wednesday, January 25, the company rating was downgraded by CLSA. Citigroup initiated the stock with “Neutral” rating in Wednesday, October 7 report. The stock has “Neutral” rating by Buckingham Research on Friday, July 24. On Tuesday, May 17 the stock rating was reinitiated by Stifel Nicolaus with “Hold”. The company was upgraded on Wednesday, August 10 by Bank of America. As per Wednesday, August 5, the company rating was maintained by Cowen & Co. The rating was upgraded by UBS to “Buy” on Friday, August 7. The rating was upgraded by Credit Suisse on Wednesday, July 27 to “Outperform”.

Since January 10, 2017, it had 0 buys, and 1 insider sale for $81,127 activity. Long Annabelle Yu sold $81,127 worth of stock or 2,310 shares.

Coach, Inc. is a design house of luxury accessories and lifestyle collections. The company has market cap of $13.42 billion. The Company’s product offering uses a range of leathers, fabrics and materials. It has a 23.25 P/E ratio. The Company’s divisions include North America, International and Stuart Weitzman.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The company has market cap of $872.60 million. The Firm specializes in the research, development and commercialization of rational genome engineering technologies. It currently has negative earnings. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

About 23,158 shares traded. Cellectis SA (ADR) (NASDAQ:CLLS) has declined 1.29% since September 26, 2016 and is downtrending. It has underperformed by 12.71% the S&P500.